Phenotypes associated with this allele

• Allele Symbol: Arhgap45^em1Ciphe
• Allele Name: endonuclease-mediated mutation 1, Centre d'ImmunoPhenomique
• Allele ID: MGI:6806175
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Arhgap45^em1Ciphe/Arhgap45^em1Ciphe	C57BL/6-Arhgap45^em1Ciphe	MGI:6827289

Genotype
MGI:6827289

hm1

• Allelic Composition: Arhgap45^em1Ciphe/Arhgap45^em1Ciphe
• Genetic Background: C57BL/6-Arhgap45^em1Ciphe

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cellular

decreased lymphocyte chemotaxis ( J:309971 )

• reduced chemotaxis of naive T and B cells in vitro in response to CCL19 (CD4+ T: 7.6x less; CD8+ T: 3.6x less, B: 2.4x less), CCL21 (CD4+ T: 10x, CD8+ T: 8.5x, B: 2.2x) and CXCL12 (CD4+ T: 5.5x, CD8+ T: 4.6x, B: 2.0x)

• 2x reduced chemokinesis (chemokine-dependent motility) of naive T cells in vitro

endocrine/exocrine glands

decreased DN1 thymic pro-T cell number ( J:309971 )

• 1.5x reduction

immune system

immune system phenotype ( J:309971 )

N • normal thymus size, with normal numbers of DN2, DN3, DN4, and DP cells

N • normal spleen morphology and cellularity, with normal T and B cell numbers

N • normal numbers of effector memory CD4+ and CD8+ T cells in lymph nodes

N • normal homing efficiency of T and B cells into spleen

N • normal activated T cell chemokine-independent motility in vitro

decreased lymphocyte chemotaxis ( J:309971 )

• reduced chemotaxis of naive T and B cells in vitro in response to CCL19 (CD4+ T: 7.6x less; CD8+ T: 3.6x less, B: 2.4x less), CCL21 (CD4+ T: 10x, CD8+ T: 8.5x, B: 2.2x) and CXCL12 (CD4+ T: 5.5x, CD8+ T: 4.6x, B: 2.0x)

• 2x reduced chemokinesis (chemokine-dependent motility) of naive T cells in vitro

decreased B cell number ( J:309971 )

• 3.2x reduction in blood

decreased CD8-positive, naive alpha-beta T cell number ( J:309971 )

• 2.2x reduction in lymph nodes, 4x-fold reduction in Peyers patches

decreased T cell number ( J:309971 )

• 3.7x reduction in blood

decreased DN1 thymic pro-T cell number ( J:309971 )

• 1.5x reduction

decreased CD4-positive, alpha-beta T cell number ( J:309971 )

• 1.3x reduction

decreased CD8-positive, alpha-beta T cell number ( J:309971 )

• 1.4x reduction

decreased naive B cell number ( J:309971 )

• 2.5x reduction in lymph nodes, 17x-fold reduction in Peyers patches

lymph node hypoplasia ( J:309971 )

• owing to reduced naive T and B cell levels

• reduced homing efficiency of T and B cells into lymph node

hematopoietic system

decreased lymphocyte chemotaxis ( J:309971 )

• reduced chemotaxis of naive T and B cells in vitro in response to CCL19 (CD4+ T: 7.6x less; CD8+ T: 3.6x less, B: 2.4x less), CCL21 (CD4+ T: 10x, CD8+ T: 8.5x, B: 2.2x) and CXCL12 (CD4+ T: 5.5x, CD8+ T: 4.6x, B: 2.0x)

• 2x reduced chemokinesis (chemokine-dependent motility) of naive T cells in vitro

decreased B cell number ( J:309971 )

• 3.2x reduction in blood

decreased CD8-positive, naive alpha-beta T cell number ( J:309971 )

• 2.2x reduction in lymph nodes, 4x-fold reduction in Peyers patches

decreased T cell number ( J:309971 )

• 3.7x reduction in blood

decreased DN1 thymic pro-T cell number ( J:309971 )

• 1.5x reduction

decreased CD4-positive, alpha-beta T cell number ( J:309971 )

• 1.3x reduction

decreased CD8-positive, alpha-beta T cell number ( J:309971 )

• 1.4x reduction

decreased naive B cell number ( J:309971 )

• 2.5x reduction in lymph nodes, 17x-fold reduction in Peyers patches

embryo

embryo phenotype ( J:309971 )

N • mice born at normal Mendelian ratios

mortality/aging

mortality/aging ( J:309971 )

N • viable